Table 3.
Gleason score and risk category upgrade rates from biopsy to prostatectomy for different biopsy modalities
| Systematic 12-Core Biopsy |
mpMRI-TRUS Biopsy |
Systematic 12-Core + mpMRI-TRUS Biopsy |
||||
|---|---|---|---|---|---|---|
| Prostatectomy Upgrade | Nonsaturation | Saturation | Nonsaturation | Saturation | Nonsaturation | Saturation |
| Gleason score: | ||||||
| No | 70 (57.4) | 40 (46.5) | 77 (63.1) | 68 (79.1) | 95 (77.9) | 74 (86.0) |
| Yes | 52 (43.1) | 46 (53.5) | 45 (36.9) | 18 (20.9) | 27 (22.1) | 12 (14.0) |
| p Value | 0.122 | – | 0.014 | – | 0.137 | – |
| Risk category: | ||||||
| No | 75 (61.5) | 48 (55.8) | 85 (69.7) | 74 (86.0) | 100 (82.0) | 80 (93.0) |
| Yes | 47 (38.5) | 38 (44.2) | 37 (30.3) | 12 (14.0) | 22 (18.0) | 6 (7.0) |
| p Value | 0.413 | – | 0.006 | – | 0.021 | – |
Pathological data from systematic and mpMRI-TRUS fusion biopsies were analyzed for maximum Gleason score and risk category, and compared with corresponding data from prostatectomy on each patient. If prostatectomy Gleason score or risk category was higher than systematic, fusion or combined biopsy Gleason score or risk category, case was deemed upgraded in corresponding biopsy category. Upgrade rates of each biopsy modality were recorded for patients with saturation biopsy and those with nonsaturation fusion biopsy of index tumor.